GSK plots reg­u­la­to­ry fil­ings for PBC itch af­ter pos­i­tive Phase 3 read­out

GSK’s liner­ix­i­bat helped re­duce itch in pa­tients with an au­toim­mune liv­er dis­ease that af­fects the bile ducts, meet­ing its pri­ma­ry end­point in a late-stage tri­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.